Rethinking and Restructuring the FDA Drug Approval Process in Light of the Vioxx Recall

By Dohrman, Amanda J. | Journal of Corporation Law, Fall 2005 | Go to article overview

Rethinking and Restructuring the FDA Drug Approval Process in Light of the Vioxx Recall


Dohrman, Amanda J., Journal of Corporation Law


I. INTRODUCTION

On September 30, 2004, Merck & Co. (Merck) announced that it would immediately withdraw its second most profitable drug, Vioxx, from worldwide markets.1 The company's announcement ignited serious concerns about the Food and Drug Administration's (FDA) pre-market approval procedures for prescription drugs. Although Merck voluntarily chose to withdraw its widely popular and profitable drug without FDA mandate, critics contend that the FDA cannot rely on private drug manufacturers to selfregulate their products. Merck's decision is a mere indicator of the substantial problems that cripple the effectiveness of FDA pharmaceutical regulatory approvals, particularly in regard to the management and use of clinical trials in the research and approval process.2 In light of the Vioxx recall, the FDA must develop a new protocol for approving commercial drugs that properly balances timely prescription drug commercialization with mindful, effective, and commercially reasonable safety standards. The FDA must do so as a collaborative effort with private drug manufacturers so that it can hold them responsible if they fail to disclose vital information to consumers or impede the PDA's drug approval review.

This Note reviews the events that caused Merck to recall Vioxx and uses Vioxx as an example to critically analyze the policies and politics of the FDA drug approval process. After outlining the basic drug approval process, this Note analyzes two significant problems that cripple the FDA drug review system. First, drug manufacturers have too much financial influence on the drug review process and pressure the FDA to approve drugs too quickly. second, current FDA review practices are inadequate because the FDA has failed to implement a national clinical drug trial registry that would inspire transparent drug development and peer review by the scientific community. To minimize these harms, the FDA ought to establish a national clinical trial registry that could be partially funded by fees paid by drug manufacturers. Lastly, this Note recommends that the FDA establish an independent review board funded by the Prescription Drug User Fee Act to regulate the clinical trial registry. This board will ensure that both the FDA and drug manufacturers comply with their responsibilities to disclose all pertinent drug information to consumers, which will make the drug approval process more translucent and effective.

II. BACKGROUND: THE DRAMA OF MERCK, Vioxx, AND THE FDA

A. The Drama of the Vioxx Recall

Merck's decision to withdraw Vioxx (generically named rofecoxib) from worldwide markets in the fall of 2004 was based on clinical trial data indicating that chronic use (18 months) of Vioxx resulted in an increased risk of cardiovascular events such as heart attacks and strokes.3 The recall was the largest and most expensive drug withdrawal in recent history; nearly 20 million Americans used Vioxx for arthritis and similar pain relief and were affected by Merck's decision.4 The withdrawal was significant because Merck had promoted Vioxx as its powerhouse prescription by investing more than $500 million in consumer and professional advertising, including a widely recognizable television ad featuring champion skater Dorothy Hammel effortlessly skating without arthritis pain by using Vioxx.5

Specifically, Vioxx is a nonsteroidal anti-inflammatory drug (NSAID) similar to aspirin and ibuprofen. It is popularly used to treat arthritis because, like all NSAIDs, Vioxx has anti-inflammatory and analgesic properties.6 Vioxx is distinct from other NSAIDs, however, because it mechanistically works as a COX-2 inhibitor. A COX-2 inhibitor specifically blocks the cyclooxygenase-2 (COX-2) enzyme that is known to cause severe gastrointestinal (GI) bleeding, but does not block the cyclooxygenase-1 (COX-1) version of the enzyme that produces desirable anti-inflammatory and analgesic effects.7 Patients who take traditional NSAIDs suffer severe GI side effects, such as GI bleeding and ulcers, because those NSAIDs operate by inhibiting both COX-1 and COX2. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Rethinking and Restructuring the FDA Drug Approval Process in Light of the Vioxx Recall
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.